share_log

Don't Ignore The Fact That This Insider Just Sold Some Shares In New Ray Medicine International Holding Limited (HKG:6108)

Don't Ignore The Fact That This Insider Just Sold Some Shares In New Ray Medicine International Holding Limited (HKG:6108)

不要忽視一個事實,這位內幕人士剛剛出售了新光醫藥國際控股有限公司(HKG:6108)的部分股份
Simply Wall St ·  2022/04/29 18:52

We note that a New Ray Medicine International Holding Limited (HKG:6108) insider, Shenglei Qian, recently sold HK$154k worth of stock for HK$1.92 per share. However we note that the sale only shrunk their holding by 0.04%.

我們注意到,新光醫藥國際控股有限公司(HKG:6108)內部人士錢勝磊最近以每股1.92港元的價格出售了價值15.4萬港元的股票。然而,我們注意到,此次出售僅使他們的持有量減少了0.04%。

Check out our latest analysis for New Ray Medicine International Holding

查看我們對新光醫藥國際控股公司的最新分析

New Ray Medicine International Holding Insider Transactions Over The Last Year

新光醫藥國際控股公司去年的內幕交易

In fact, the recent sale by Shenglei Qian was the biggest sale of New Ray Medicine International Holding shares made by an insider individual in the last twelve months, according to our records. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. The silver lining is that this sell-down took place above the latest price (HK$0.98). So it may not tell us anything about how insiders feel about the current share price.

事實上,根據我們的記錄,最近錢聖磊的出售是過去12個月內由內部人士持有的新光醫藥國際控股股份的最大一筆出售。我們通常不喜歡看到內幕銷售,但售價越低,我們就越擔心。一線希望是,此次拋售發生在最新股價(0.98港元)之上。因此,它可能不會告訴我們任何關於內部人士對當前股價的感受。

The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

下面的圖表顯示了過去一年的內幕交易(按公司和個人)。如果你點擊圖表,你可以看到所有的個人交易,包括股票價格、個人和日期!

SEHK:6108 Insider Trading Volume April 29th 2022
聯交所:6108內幕交易量2022年4月29日

If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: insiders have been buying them).

如果你喜歡購買內部人士正在買入的股票,而不是拋售,那麼你可能會喜歡這一點免費公司名單。(提示:內部人士一直在買入這些股票)。

Does New Ray Medicine International Holding Boast High Insider Ownership?

新光醫藥國際控股公司是否擁有高度的內部人持股?

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. We usually like to see fairly high levels of insider ownership. New Ray Medicine International Holding insiders own 47% of the company, currently worth about HK$766m based on the recent share price. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

看看一家公司的內部人持股總數,可以幫助你瞭解他們是否與普通股股東很好地結合在一起。我們通常希望看到相當高水平的內部人士持股。新光醫藥國際控股有限公司內部人士持有該公司47%的股份,按近期股價計算,目前價值約7.66億港元。大多數股東將樂於看到這種內部人持股,因為這表明管理層的激勵與其他股東很好地結合在一起。

So What Do The New Ray Medicine International Holding Insider Transactions Indicate?

那麼,新光醫藥國際控股公司的內幕交易表明了什麼?

An insider hasn't bought New Ray Medicine International Holding stock in the last three months, but there was some selling. And even if we look at the last year, we didn't see any purchases. While insiders do own a lot of shares in the company (which is good), our analysis of their transactions doesn't make us feel confident about the company. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing New Ray Medicine International Holding. Case in point: We've spotted 1 warning sign for New Ray Medicine International Holding you should be aware of.

一位內部人士在過去三個月裏沒有買入新光醫藥國際控股公司的股票,但出現了一些拋售。即使我們看看去年,我們也沒有看到任何購買。雖然內部人士確實持有該公司的大量股份(這很好),但我們對他們交易的分析並不能讓我們對該公司充滿信心。除了瞭解正在進行的內幕交易外,識別新光醫藥國際控股公司面臨的風險也是有益的。舉個例子:我們發現了新光醫藥國際控股公司的一個警告標誌,你應該知道。

But note: New Ray Medicine International Holding may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

但請注意:新光醫藥國際控股公司可能不是最值得買入的股票。所以讓我們來看看這個免費高淨資產收益率和低負債的有趣公司名單。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

就本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前負責公開市場交易和私人處置,但不包括衍生品交易。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有什麼反饋嗎?擔心內容嗎?保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
這篇由《華爾街日報》撰寫的文章本質上是籠統的。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。簡單地説,華爾街在提到的任何股票中都沒有頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論